Fenoldopam: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Fenoldopam}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SS}} | ||
'''''For patient information about | '''''For patient information about Fenoldopam, click [[Fenoldopam (patient information)|here]].''''' | ||
{{SB}} | {{SB}} CORLOPAM<sup>®</sup> | ||
==Overview== | ==Overview== | ||
'''Fenoldopam mesylate''' ('''Corlopam''') is a [[drug]] and [[Synthetic chemical|synthetic]] [[benzazepine]] [[chemical derivative|derivative]] which acts as a [[binding selectivity|selective]] [[D1 receptor|D<sub>1</sub> receptor]] [[partial agonist]].<ref>{{cite journal |author=Grenader A, Healy DP |title=Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells |journal=J. Pharmacol. Exp. Ther. |volume=258 |issue=1 |pages=193–8 |date=July 1991 |pmid=1677038 |doi= |url=}}</ref> Fenoldopam is used as an [[antihypertensive]] agent.<ref name="pmid17000789">{{cite journal |author=Oliver WC, Nuttall GA, Cherry KJ, Decker PA, Bower T, Ereth MH |title=A comparison of fenoldopam with dopamine and sodium nitroprusside in patients undergoing cross-clamping of the abdominal aorta |journal=Anesth. Analg. |volume=103 |issue=4 |pages=833–40 |date=October 2006 |pmid=17000789 |doi=10.1213/01.ane.0000237273.79553.9e |url=http://www.anesthesia-analgesia.org/cgi/pmidlookup?view=long&pmid=17000789}}</ref> It was approved by the [[Food and Drug Administration]] (FDA) in September 1997.<ref>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory accessed November 14, 2011</ref> | |||
==Category== | ==Category== | ||
Benzazepines;D1-receptor agonists;Phenols;Organochlorides;Cardiovascular Drugs | |||
====Label Title==== | ====Label Title==== | ||
''' [[ | ''' [[Fenoldopam indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Fenoldopam dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Fenoldopam dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[ | '''| [[Fenoldopam contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Fenoldopam warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Fenoldopam adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Fenoldopam drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[Fenoldopam use in specific populations|Use in Specific Populations]]''' | ||
'''| [[ | '''| [[Fenoldopam overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Fenoldopam description|Description]]''' | ||
'''| [[ | '''| [[Fenoldopam clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Fenoldopam nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[ | '''| [[Fenoldopam clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Fenoldopam how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[ | '''| [[Fenoldopam patient counseling information|Patient Counseling Information]]''' | ||
'''| [[ | '''| [[Fenoldopam labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or α- or β-adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration. | |||
In animals, fenoldopam has vasodilating effects in coronary, renal, mesenteric and peripheral arteries. All vascular beds, however, do not respond uniformly to fenoldopam. Vasodilating effects have been demonstrated in renal efferent and afferent arterioles. | |||
== References == | |||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | {{Sympatholytic antihypertensives}} | ||
[[Category: | {{Dopaminergics}} | ||
[[Category:Benzazepines]] | |||
[[Category:D1-receptor agonists]] | |||
[[Category:Phenols]] | |||
[[Category:Organochlorides]] | |||
Revision as of 03:03, 27 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Fenoldopam, click here.
Synonyms / Brand Names: CORLOPAM®
Overview
Fenoldopam mesylate (Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.[1] Fenoldopam is used as an antihypertensive agent.[2] It was approved by the Food and Drug Administration (FDA) in September 1997.[3]
Category
Benzazepines;D1-receptor agonists;Phenols;Organochlorides;Cardiovascular Drugs
Label Title
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or α- or β-adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.
In animals, fenoldopam has vasodilating effects in coronary, renal, mesenteric and peripheral arteries. All vascular beds, however, do not respond uniformly to fenoldopam. Vasodilating effects have been demonstrated in renal efferent and afferent arterioles.
References
- ↑ Grenader A, Healy DP (July 1991). "Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells". J. Pharmacol. Exp. Ther. 258 (1): 193–8. PMID 1677038.
- ↑ Oliver WC, Nuttall GA, Cherry KJ, Decker PA, Bower T, Ereth MH (October 2006). "A comparison of fenoldopam with dopamine and sodium nitroprusside in patients undergoing cross-clamping of the abdominal aorta". Anesth. Analg. 103 (4): 833–40. doi:10.1213/01.ane.0000237273.79553.9e. PMID 17000789.
- ↑ http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory accessed November 14, 2011